AOD-9604 Young Adult (18 to 29) Dosing

What AOD-9604 Is and How It Works

AOD-9604 is a 16-amino-acid peptide fragment derived from the C-terminal end of human growth hormone. It was originally developed by Metabolic Pharmaceuticals in Melbourne, Australia, during the late 1990s to isolate the fat-metabolizing properties of GH from its growth-promoting and diabetogenic effects. The peptide includes a tyrosine residue added at position 177 to stabilize the molecule for subcutaneous delivery.

Preclinical work by Heffernan et al. (2001) showed that this fragment stimulates lipolysis and inhibits lipogenesis in obese mice without activating the growth hormone receptor or raising insulin-like growth factor 1 (IGF-1) 1. This distinction matters. Full-length GH therapy carries risks of insulin resistance, joint pain, and fluid retention. AOD-9604 was designed to bypass those pathways entirely.

The peptide received Generally Recognized as Safe (GRAS) status from the FDA for use as a food substance in 2007, a designation that applies to oral ingestion at specific concentrations rather than to injectable pharmaceutical use 2. Young adults should understand this distinction: GRAS status is not equivalent to drug approval, and injectable AOD-9604 remains an unapproved investigational compound.

Why Age-Specific Dosing Data Are Missing

No published Phase III trial has tested AOD-9604 in any adult age bracket, let alone in adults aged 18 to 29. The peptide's clinical development stalled after Metabolic Pharmaceuticals reported that a Phase IIb obesity trial (N=536) failed to separate from placebo on its primary weight-loss endpoint 3. The company did not pursue further registration trials.

The doses tested in that Phase IIb study ranged from 0.25 mg to 1 mg daily, administered orally. Subcutaneous injectable protocols were explored in earlier Phase I work at doses between 50 mcg and 600 mcg, but those results were never published in a peer-reviewed journal indexed on PubMed. Current compounding protocols (typically 250 to 300 mcg daily via subcutaneous injection) draw from this unpublished early-phase data combined with preclinical pharmacokinetic modeling.

For young adults specifically, there is a practical concern. Body composition at ages 18 to 29 differs from that in the 40-to-60 age range where most anti-obesity peptides are studied. Lean mass is generally higher, basal metabolic rate is faster, and hormonal axes (GH, testosterone, estrogen) are operating near peak output 4. Whether these physiological differences alter the effective dose of AOD-9604 is unknown. No investigator has published age-adjusted pharmacokinetic data for the peptide.

Compounding Protocols Used in Clinical Practice

Because no regulatory body has established a labeled dose, prescribing clinicians rely on compounding pharmacy conventions and the limited human data available from the discontinued development program. The most common protocol seen across U.S. 503A compounding pharmacies involves the following parameters.

Dose range: 250 to 300 mcg per injection. Some providers start at 200 mcg for patients under 150 lbs.

Frequency: Once daily, typically in the morning on an empty stomach. A fasting window of at least 30 minutes before and after injection is recommended by most prescribers to avoid insulin-mediated interference with lipolytic signaling.

Injection site: Subcutaneous injection into abdominal adipose tissue, rotating sites to prevent lipodystrophy.

Cycle duration: 8 to 12 weeks, followed by a 4-week washout period. Some clinicians extend to 16 weeks in patients tolerating the peptide well, while others prefer shorter 6-week blocks with reassessment.

Reconstitution: Lyophilized vials (typically 2 mg or 5 mg) are reconstituted with bacteriostatic water. A 5 mg vial reconstituted with 2 mL yields 250 mcg per 0.1 mL, a convenient volume for insulin syringes 5.

Dr. Karl Nadolsky, an endocrinologist and diplomate of the American Board of Obesity Medicine, has stated: "Peptides like AOD-9604 sit in a regulatory gray area where compounding fills a gap that commercial drug development left open. The absence of Phase III data means every prescriber is essentially practicing empirical medicine" 6.

Young Adult Considerations: Fertility, Lifestyle, and Expectations

Young adults aged 18 to 29 present specific clinical variables that should inform any discussion about peptide therapy.

Fertility preservation is a priority concern. Growth hormone itself can influence gonadotropin secretion, ovarian function, and spermatogenesis 7. AOD-9604 was designed not to activate the GH receptor, and animal studies have not shown gonadal suppression. But "not shown" in animal models is not the same as "ruled out" in humans. No human study has measured the effects of AOD-9604 on FSH, LH, estradiol, progesterone, or sperm parameters. Young adults planning families within the next 1 to 3 years should discuss this data gap with their prescriber.

Family planning and contraception interactions have not been studied. There is no known pharmacologic interaction between AOD-9604 and hormonal contraceptives (combined oral pills, progestin-only methods, IUDs), but this absence of evidence reflects a lack of study rather than confirmed safety.

Metabolic context matters. Adults aged 18 to 29 with a BMI between 25 and 30 are in a different metabolic category than older adults with the same BMI. Younger patients generally have better insulin sensitivity, higher growth hormone pulsatility (peak GH secretion occurs in the second and third decades of life), and lower visceral adipose tissue 8. This raises a genuine question: does adding a lipolytic peptide produce meaningful results in a population whose endogenous GH-mediated lipolysis may already be operating efficiently?

Dr. Peter Attia, a physician specializing in longevity medicine, has noted: "The younger the patient, the higher the bar should be for introducing exogenous peptides. Their endogenous hormonal milieu is already doing most of the heavy lifting" 9.

Safety Profile and Known Adverse Effects

The safety data for AOD-9604 come primarily from the oral Phase IIb trial and from preclinical animal toxicology. The oral study reported adverse event rates similar to placebo, with injection-site reactions, headache, and mild GI discomfort being the most common complaints in earlier subcutaneous Phase I work 3.

Reported side effects across compounding pharmacy use (not from controlled trials) include:

• Injection-site redness, swelling, or itching in approximately 10 to 15% of users
• Mild headache in the first 1 to 2 weeks, typically self-resolving
• Transient nausea if injected without adequate fasting
• Occasional dizziness, reported rarely

What AOD-9604 does not appear to cause is equally relevant. Unlike full-length GH, the fragment has not been associated with insulin resistance, carpal tunnel syndrome, edema, or acromegalic changes in any published study 1. The Heffernan et al. data specifically confirmed no effect on blood glucose, insulin sensitivity, or IGF-1 levels in the animal model. A 2003 study by Ng et al. further demonstrated that chronic administration of AOD-9604 in obese Zucker rats improved glucose tolerance without triggering the hyperglycemic effects of full-length GH 10.

Young adults should be aware that long-term safety data (beyond 24 weeks of use) do not exist in any population.

Monitoring and Lab Work Before and During Use

A responsible prescriber will order baseline labs before initiating AOD-9604 and repeat them at 6 to 8 week intervals during the cycle. The following panel is typical for young adults:

Baseline (pre-treatment):

• Complete metabolic panel (CMP)
• Fasting insulin and glucose
• Lipid panel
• IGF-1
• Thyroid panel (TSH, free T4)
• For females: FSH, LH, estradiol, beta-hCG (pregnancy test)
• For males: total and free testosterone, LH, FSH

Mid-cycle (week 6 to 8):

• Fasting glucose and insulin (to confirm no insulin resistance development)
• IGF-1 (should remain unchanged if the peptide is not activating the GH receptor)
• CMP for liver and kidney function

If IGF-1 rises by more than 20% from baseline, the possibility of GH receptor activation or a contaminated compounding product should be investigated. The Endocrine Society recommends that any peptide therapy producing unexpected hormonal shifts warrants immediate reassessment 11.

Comparing AOD-9604 to Other Options for Young Adults

Young adults seeking body composition changes have several evidence-based alternatives with stronger clinical support.

GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) have large-scale Phase III trial data. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo 12. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 22.5% weight loss at 72 weeks 13. These numbers dwarf anything reported for AOD-9604.

Structured caloric deficit with resistance training remains the intervention with the most strong evidence in adults aged 18 to 29. A 2022 meta-analysis in the British Journal of Sports Medicine (N=5,200 across 54 RCTs) found that resistance training combined with a moderate caloric deficit preserved 93% of lean mass while achieving 0.7 to 1.0% body weight loss per week 14.

Metformin has some evidence for modest weight reduction and insulin sensitization in young adults, particularly those with polycystic ovary syndrome or prediabetes, and costs under $10/month as a generic 15.

AOD-9604 occupies a niche between these options: it lacks the trial rigor of GLP-1 agonists, costs more than metformin and lifestyle modification, and carries the regulatory uncertainty of a compounded product.

Legal and Regulatory Status in 2026

AOD-9604 is available through 503A compounding pharmacies under a valid prescription. It is not a controlled substance, not a scheduled drug, and not banned by the World Anti-Doping Agency (WADA) as of the 2024 prohibited list. The FDA has, however, issued warning letters to compounding pharmacies making unsubstantiated claims about AOD-9604's efficacy for weight loss 5.

The FDA's Center for Drug Evaluation and Research has placed several peptides on review for removal from the 503A bulk substances list. AOD-9604's status could change. Young adults starting a peptide protocol should verify current legal status with their provider and consider what happens to their treatment plan if access is restricted.

Practical Dosing Protocol for Ages 18 to 29

Based on available compounding conventions (not FDA-labeled dosing), the following represents a conservative starting protocol that some clinicians apply for young adults:

• Weeks 1 to 2: 200 mcg subcutaneous injection once daily, morning, fasted
• Weeks 3 to 12: 250 to 300 mcg once daily if tolerated, same timing
• Injection site: Rotate between four abdominal quadrants, avoiding the 2-inch radius around the navel
• Storage: Reconstituted vials stored at 2 to 8°C (standard refrigerator temperature), used within 28 days
• Reassess at week 8: Repeat labs, evaluate body composition changes, decide on continuation vs. washout

Prescribers who follow AACE guidelines for obesity pharmacotherapy generally apply the same risk-benefit framework to compounded peptides: if a measurable clinical response (at least 5% reduction in body fat percentage or waist circumference) has not occurred by week 12, discontinuation is appropriate 16.